The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients.

Yu-Min Huang, Chun-Han Hou, Sheng-Mou Hou, Rong-Sen Yang
{"title":"The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients.","authors":"Yu-Min Huang,&nbsp;Chun-Han Hou,&nbsp;Sheng-Mou Hou,&nbsp;Rong-Sen Yang","doi":"10.4137/cmo.s531","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The author intended to clarify the therapeutic effect and prognostic factors of metastasectomy and timing of pulmonary metastases in osteosarcoma patents.</p><p><strong>Methods: </strong>Data was obtained retrospectively on all consecutive osteosarcoma patients from 1985 to 2005 in author's institute. Fifty-two patients with pulmonary nodules were identified, including 24 patients undergoing pulmonary metastasectomy treatment. These patients were categorized into four groups: group 1, patients with lung metastases at the initial presentation; group 2, lung metastases identified during the period of pre-operative chemotherapy; group 3, lung metastases identified during period of the post-operative che motherapy; group 4, lung metastases identified after therapy for the primary osteosarcoma completed.</p><p><strong>Results: </strong>In our study, the 2-, 3-, and 5-year overall survival rates for 52 patients were 49%, 39% and 20%. The 2-year overall survival rates were 18% for group 1, 32% for group 3, and 70% for group 4 (p < 0.001). The 5-year overall survival rate was 34% for group 4. Patients who underwent metastesectomy showed a better survival outcome as compared with the patients not undergoing metastasectomy (p = 0.003). The 2-year and 5-year overall survival rates of only one lung metastatic nodule were 62% and 50%, and for initially multiple lung metastatic nodules, 45% and 5%, respectively. In addition, the patients presented with lung metastases had a worse prognosis as compared with those without initial lung metastases (p = 0.0001).</p><p><strong>Conclusions: </strong>The patients having single metastatic nodule showed a better prognosis than those with multiple lung nodules. Furthermore, those patients who underwent metastasectomy survived longer than those not undergoing metastasectomy. Patients who had late metastases after complete chemotherapy had a better prognosis; whereas those who had metastases identified at the initial presentation predicted a poor prognosis.</p>","PeriodicalId":88451,"journal":{"name":"Clinical medicine. Oncology","volume":"3 ","pages":"99-105"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/cmo.s531","citationCount":"42","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical medicine. Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/cmo.s531","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 42

Abstract

Background: The author intended to clarify the therapeutic effect and prognostic factors of metastasectomy and timing of pulmonary metastases in osteosarcoma patents.

Methods: Data was obtained retrospectively on all consecutive osteosarcoma patients from 1985 to 2005 in author's institute. Fifty-two patients with pulmonary nodules were identified, including 24 patients undergoing pulmonary metastasectomy treatment. These patients were categorized into four groups: group 1, patients with lung metastases at the initial presentation; group 2, lung metastases identified during the period of pre-operative chemotherapy; group 3, lung metastases identified during period of the post-operative che motherapy; group 4, lung metastases identified after therapy for the primary osteosarcoma completed.

Results: In our study, the 2-, 3-, and 5-year overall survival rates for 52 patients were 49%, 39% and 20%. The 2-year overall survival rates were 18% for group 1, 32% for group 3, and 70% for group 4 (p < 0.001). The 5-year overall survival rate was 34% for group 4. Patients who underwent metastesectomy showed a better survival outcome as compared with the patients not undergoing metastasectomy (p = 0.003). The 2-year and 5-year overall survival rates of only one lung metastatic nodule were 62% and 50%, and for initially multiple lung metastatic nodules, 45% and 5%, respectively. In addition, the patients presented with lung metastases had a worse prognosis as compared with those without initial lung metastases (p = 0.0001).

Conclusions: The patients having single metastatic nodule showed a better prognosis than those with multiple lung nodules. Furthermore, those patients who underwent metastasectomy survived longer than those not undergoing metastasectomy. Patients who had late metastases after complete chemotherapy had a better prognosis; whereas those who had metastases identified at the initial presentation predicted a poor prognosis.

Abstract Image

Abstract Image

Abstract Image

骨肉瘤患者的转移性切除及肺转移时机对预后的影响。
背景:作者旨在阐明转移性骨肉瘤的治疗效果、预后因素和肺转移的时机。方法:回顾性分析1985 ~ 2005年本院所有骨肉瘤患者的资料。发现52例肺结节患者,其中24例接受肺转移切除术治疗。这些患者被分为四组:第一组,首次出现肺转移的患者;2组:术前化疗期间发现的肺转移灶;3组:术后化疗期间发现的肺转移灶;第4组,原发性骨肉瘤治疗完成后发现肺转移。结果:在我们的研究中,52例患者的2、3、5年总生存率分别为49%、39%和20%。第1组的2年总生存率为18%,第3组为32%,第4组为70% (p < 0.001)。第4组5年总生存率为34%。与未行转移瘤切除术的患者相比,行转移瘤切除术的患者生存率更高(p = 0.003)。仅一个肺转移结节的2年和5年总生存率分别为62%和50%,最初多发肺转移结节的2年和5年总生存率分别为45%和5%。此外,出现肺转移的患者预后较未出现肺转移的患者差(p = 0.0001)。结论:单发转移结节患者预后优于多发转移结节患者。此外,接受转移瘤切除术的患者比未接受转移瘤切除术的患者存活时间更长。完全化疗后晚期转移的患者预后较好;而那些在最初表现时就有转移的患者预后较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信